Daewoong Pharmaceutical Co., Ltd, a world-leading botulinum toxin manufacturer 
in Korea, announced its participation in IMCAS Asia 2019 held in Bali, 
Indonesia July 5-7, 2019 to introduce the excellence of BEAUTEM 
(Prabotulinumtoxin A, global brand name: NABOTA).

Photo - https://photos.prnasia.com/prnh/20190709/2517147-1 

The 13th year of IMCAS (International Master Course on Aging Science) Asia is 
one of the top international conferences for plastic surgery, dermatology and 
aesthetic science. This year, around 85 corporate participants and 2,200 
physicians had the opportunity to participate in the event. 

Daewoong hosted an exhibition booth and a stand-alone symposium to present the 
excellence of BEAUTEM and meaning of FDA approval as the first 900 kDa 
botulinum toxin after Botox. Dr. Hema Sundaram, a US dermatologist who 
participated in the global clinical trial and one of the faculty members of 
IMCAS Asia, had the opportunity to speak about a massive global study that 
involved over 2,100 subjects in the US, EU, and Canada. 

Dr. Hema Sundaram said, "Every physician wants to treat their patients with a 
trustable drug product. Botulinum toxin drug product manufactured by Daewoong 
Pharmaceutical had successfully proved its excellent efficacy and safety 
through FDA approval based on the fact that its non-inferiority results to 
Botox in all aspects of wrinkle improvement and stability in large-scale global 
clinical trials."

Alongside the exhibition, the NABOTA Aesthetic Forum (NAF in Bali) was held by 
Daewoong Pharmaceutical to invite more than 30 dermatologists and aesthetic 
surgeons from 6 different countries. This forum was prepared by Daewoong 
Pharmaceutical for the 5th straight year to share the opportunity to explore 
and update the new techniques and trends in the field.

With regards of first botulinum toxin clinical study in Vietnam, Dr. Pham Xuan 
Hung said, "In comparison study with BEAUTEM versus Botox, we have confirmed 
non-inferiority result to Botox, and it was an opportunity to confirm the 
excellent efficacy and safety of BEAUTEM from the Vietnamese as well." 

"Throughout IMCAS Asia 2019, we have had a good opportunity to prove the 
excellence of BEAUTEM to global physicians. Based on its proven excellence in 
quality and manufacturing process, we expect the significant increase of 
overseas sales and will continuously promote BEAUTEM's excellence and 
strengthen its position as a global brand," said Seongsoo Park, Executive 
Director of NABOTA Business Department in Daewoong Pharmaceutical. 

SOURCE  Daewoong Pharmaceutical Co., Ltd